Epigenetic Drugs May Be Key to Improving Cancer Patients’ Response to Immunotherapies

Epigenetic Drugs May Be Key to Improving Cancer Patients’ Response to Immunotherapies
In the past decade, immunotherapy treatment approaches designed to fight cancer using the body’s natural defenses have attracted tremendous attention. This led to advances in the synthesis and development of new agents, some of which have now reached the clinic. Several successful immunotherapy studies were presented at this summer’s American Society of Clinical Oncology (ASCO) conference in

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *